NCT01661179View on ClinicalTrials.gov

Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

July 31, 2014

Conditions
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Interventions
DRUG

Vandetanib 300mg

300 mg oral dose once daily (100 mg x 3 tablets)

Trial Locations (4)

Unknown

Research Site, Fukuoka

Research Site, Kobe

Research Site, Kōtoku

Research Site, Shinjuku-ku

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01661179 - Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | Biotech Hunter | Biotech Hunter